PMID- 26251624
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20150807
LR  - 20200929
IS  - 1178-7007 (Print)
IS  - 1178-7007 (Electronic)
IS  - 1178-7007 (Linking)
VI  - 8
DP  - 2015
TI  - Anti-atherosclerotic effects of sitagliptin in patients with type 2 diabetes 
      mellitus.
PG  - 339-45
LID - 10.2147/DMSO.S84545 [doi]
AB  - BACKGROUND: Advanced glycation end products, selectins, and adiponectin play 
      important roles in the development of atherosclerosis in individuals with 
      diabetes. Sitagliptin has been shown to reduce the concentration of glycated 
      hemoglobin in diabetic patients. However, its effects on soluble receptor for 
      advanced glycation end products (sRAGEs), selectins, and adiponectin in these 
      patients are poorly understood. This study was conducted to assess the effects of 
      sitagliptin on the circulating levels of sRAGEs, monocyte chemoattractant 
      protein-1 (MCP-1), selectins, and adiponectin in patients with type 2 diabetes. 
      METHODS: Diabetic patients eligible for sitagliptin monotherapy or combination 
      therapy (eg, sitagliptin plus a sulfonylurea) were administered sitagliptin (50 
      mg/day) for 6 months. Levels of soluble P-selectin (sP-selectin), soluble 
      E-selectin (sE-selectin), soluble vascular cell adhesion molecule-1 (sVCAM-1), 
      MCP-1, sRAGEs, and adiponectin were measured by ELISA at baseline and after 3 and 
      6 months of treatment. RESULTS: At baseline, the levels of MCP-1, sP-selectin, 
      sE-selectin, and sVCAM-1 were higher and the level of adiponectin was lower in 
      diabetic patients than in nondiabetic patients. Sitagliptin therapy for 3 and 6 
      months significantly reduced plasma levels of sP-selectin, sE-selectin, sVCAM-1, 
      and MCP-1 relative to baseline, while significantly increasing adiponectin 
      levels. sRAGEs did not exhibit a statistical significance, although there was an 
      increasing tendency. Furthermore, the reductions in sP-selectin, sE-selectin, 
      sVCAM-1, and MCP-1 during sitagliptin therapy were significantly greater in 
      responders, defined as patients with a significant increase in adiponectin 
      levels, than in nonresponders. In contrast, responders showed a significant 
      increase in the plasma concentration of sRAGEs. CONCLUSION: Sitagliptin shows an 
      adiponectin-dependent anti-atherothrombotic effect, which may be beneficial for 
      primary prevention of atherothrombosis, in patients with type 2 diabetes.
FAU - Omoto, Seitaro
AU  - Omoto S
AD  - Division of Internal Medicine, Korigaoka Yukeikai Hospital, Kansai Medical 
      University, Osaka, Japan.
FAU - Taniura, Takehito
AU  - Taniura T
AD  - Division of Internal Medicine, Daiwa Hospital, Kansai Medical University, Osaka, 
      Japan.
FAU - Nishizawa, Tohru
AU  - Nishizawa T
AD  - First Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
FAU - Tamaki, Takeshi
AU  - Tamaki T
AD  - First Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
FAU - Shouzu, Akira
AU  - Shouzu A
AD  - Division of Internal Medicine, Saiseikai Izuo Hospital, Osaka, Japan.
FAU - Nomura, Shosaku
AU  - Nomura S
AD  - First Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
LA  - eng
PT  - Journal Article
DEP - 20150727
PL  - New Zealand
TA  - Diabetes Metab Syndr Obes
JT  - Diabetes, metabolic syndrome and obesity : targets and therapy
JID - 101515585
PMC - PMC4524383
OTO - NOTNLM
OT  - adiponectin
OT  - sRAGE
OT  - sVCAM-1
OT  - selectins
OT  - sitagliptin
OT  - type 2 diabetes mellitus
EDAT- 2015/08/08 06:00
MHDA- 2015/08/08 06:01
PMCR- 2015/07/27
CRDT- 2015/08/08 06:00
PHST- 2015/08/08 06:00 [entrez]
PHST- 2015/08/08 06:00 [pubmed]
PHST- 2015/08/08 06:01 [medline]
PHST- 2015/07/27 00:00 [pmc-release]
AID - dmso-8-339 [pii]
AID - 10.2147/DMSO.S84545 [doi]
PST - epublish
SO  - Diabetes Metab Syndr Obes. 2015 Jul 27;8:339-45. doi: 10.2147/DMSO.S84545. 
      eCollection 2015.